GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Operating Income

Joinn Laboratories (China) Co (SHSE:603127) Operating Income : ¥551 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Operating Income?

Joinn Laboratories (China) Co's Operating Income for the three months ended in Mar. 2024 was ¥10 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥551 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Joinn Laboratories (China) Co's Operating Income for the three months ended in Mar. 2024 was ¥10 Mil. Joinn Laboratories (China) Co's Revenue for the three months ended in Mar. 2024 was ¥325 Mil. Therefore, Joinn Laboratories (China) Co's Operating Margin % for the quarter that ended in Mar. 2024 was 3.13%.

Joinn Laboratories (China) Co's 5-Year average Growth Rate for Operating Margin % was -0.60% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Joinn Laboratories (China) Co's annualized ROC % for the quarter that ended in Mar. 2024 was 0.60%. Joinn Laboratories (China) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -36.87%.


Joinn Laboratories (China) Co Operating Income Historical Data

The historical data trend for Joinn Laboratories (China) Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Operating Income Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 199.27 301.80 451.94 717.17 633.64

Joinn Laboratories (China) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.12 145.96 144.48 250.08 10.15

Joinn Laboratories (China) Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥551 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Joinn Laboratories (China) Co  (SHSE:603127) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Joinn Laboratories (China) Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=40.616 * ( 1 - 6.74% )/( (6507.395 + 6194.655)/ 2 )
=37.8784816/6351.025
=0.60 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10027.16 - 283.499 - ( 3236.266 - max(0, 1467.365 - 7121.967+3236.266))
=6507.395

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9733.254 - 231.326 - ( 3307.273 - max(0, 1502.564 - 6971.164+3307.273))
=6194.655

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Joinn Laboratories (China) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1169.908/( ( (988.778 + max(2300.283, 0)) + (991.649 + max(2066.122, 0)) )/ 2 )
=-1169.908/( ( 3289.061 + 3057.771 )/ 2 )
=-1169.908/3173.416
=-36.87 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(206.014 + 1863.082 + 1671.052) - (283.499 + 0 + 1156.366)
=2300.283

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(189.795 + 1694.742 + 1656.185) - (231.326 + 0 + 1243.274)
=2066.122

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Joinn Laboratories (China) Co's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=10.154/324.809
=3.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Joinn Laboratories (China) Co Operating Income Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co (SHSE:603127) Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yao Da Lin Director
Sun Yun Xia Director
Zuo Cong Lin Director
Gao Da Peng Director
Li Ye Supervisors
Gu Xiao Lei Director
Feng Yu Xia Director
Gu Jing Liang senior management
Yu Ai Shui senior management
Yin Li Li Supervisors
Sun Hui Ye Supervisors
Gu Mei Fang Director

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines